Lyme Borreliosis

  • M. Möhrenschlager


Lyme borreliosis is a multi-systemic disease that can be caused by three different species of the Borrelia burgdorferi sensu lato complex: B. afzelii, B. garinii, and B. sensu stricto. In Europe) all three species can be found in patients with Lyme disease) where in the United States only B. burgdorferi sensu stricto plays a role in humans. Cases of Lyme borreliosis have been reported from all temperate regions of North America, Europe, and Asia. The main vector for the transfer of the organism in Europe is the tick Ixodes ricinus; in the United States primarily Ixodes scapularis and Ixodes pacificus. Ixodes develops in three stages — from larvae to nymph to adult tick. The ticks become infected by feeding on small mammals or certain birds which serve as reservoirs for Borrelia burgdorferi. In central Europe between 8–34% of 1. ricinus have been found to carry Borrelia burgdorferi.


Lyme Disease Borrelia Burgdorferi Lyme Borreliosis Adult Tick Erythema Migrans 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Academy of Pediatrics. Committee on Infectious Diseases: Prevention of Lyme disease. Pediatrics 105:142–147 (2000)CrossRefGoogle Scholar
  2. Anonymus. CDC Lyme WHO-CC.
  3. Arnez M., Radsel-Medvescek A., Pleterski-Rigler D., Ruzic-Sabljic E., Strle F: Comparison of cefuroxime axetil and phenoxymethyl penicillin for the treatment of children with solitary erythema migrans. Wiener Klinische Wochenschrift 111:916–922 (1999)PubMedGoogle Scholar
  4. Beran J., de Clercq N., Dieussaert I., van Hoecke C.: Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2–5 years old. Clinical Infectious Diseases 31:1504–1507 (2000)PubMedCrossRefGoogle Scholar
  5. Centers for Disease Control and Prevention: Lyme disease — United States, 1999. Journal of the American Medical Association 285:1698–1699 (2001)CrossRefGoogle Scholar
  6. Feder H.M.: Pitfalls in the diagnosis and treatment of Lyme disease in children. Journal of the American Medical Association 274:66–68 (1995)PubMedCrossRefGoogle Scholar
  7. Feder H.M., Beran J., van Hoecke C., Abraham B., de Clercq N., Buscarino C., Parenti D.L.: Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. Journal of Pediatrics 135: 575–579 (1999)PubMedCrossRefGoogle Scholar
  8. Klein J.O.: History of macrolide use in pediatrics. Pediatric Infectious Diseases Journal 16:427–431 (1997)CrossRefGoogle Scholar
  9. Oschmann P., Kraiczy P., Halperin J., Brade V. (eds): Lyme Borreliosis and Tick-borne Encephalitis. Unimed, Bremen (1999)Google Scholar
  10. Paul H., Gerth H.J., Ackermann R.: Infectiousness for humans of Ixodes ricinus containing Borrelia burgdorferi. Zentralblatt fur Bakteriologie und Hygiene (A) 263:473–476 (1986)Google Scholar
  11. Piesman J., Mather T.N., Sinsky R.J., Spielman A.: Duration of tick attachment and Borrelia burgdorferi transmission. Journal of Clinical Microbiology 25:557–558 (1987)PubMedGoogle Scholar
  12. Salazaar J.C., Gerber M.A., Goff C.W.: Long-term outcome of Lyme disease in children given early treatment. The Journal of Pediatrics 122:591–593 (1993)CrossRefGoogle Scholar
  13. Shapiro E.D., Gerber M.A.: Lyme disease. Clinical Infectious Diseases 31:533–542 (2000)PubMedCrossRefGoogle Scholar
  14. Sigal L.H., Zahradnik J.M., Lavin P., Patella S.J., Bryant G., Haselby R., Hilton E., Kunkel M., AdlerKlein D., Doherty T., Evans J., Malawista S.E., and the recombinant outer surface protein A Lyme disease vaccine study consortium: A vaccine consisting of recombinant Borrelia burgdorferi outersurface protein A to prevent Lyme disease. New England Journal of Medicine 339:216–222 (1998)PubMedCrossRefGoogle Scholar
  15. Steere A.C., Sikand V.K., Meurice E, Parenti D.L., Fikrig E., Schoen R.T., Nowakowski J., Schmid C.H., Laukamp S., Buscarino C., Krause D.C., and the Lyme disease vaccine study group: Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. New England Journal of Medicine 339:209–215 (1998)PubMedCrossRefGoogle Scholar
  16. Weber K., Pfister H.W.: Clinical management of Lyme borreliosis. Lancet 343:1017–1020 (1994)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. Möhrenschlager

There are no affiliations available

Personalised recommendations